Evolus EOLS
NASDAQ EOLS
$6.81 -0.17 (-2.44%)
At close: Nov 10, 2026 · 4:00 PM EST

Evolus (EOLS) Receivables - Other (2017)

Updated

Evolus (EOLS) posted Receivables - Other of $72.64 million for Q4 2017.

Analysis

Evolus (EOLS) Receivables - Other (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Evolus 455.33 Mn 264.84 Mn 50.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 72.64 Mn
API Access

Evolus Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=EOLS&period=max&api_key=YOUR_API_KEY